: Recombinant Factor VIII, Plasma-Derived Factor VIII, Extended Half-life Factor VIII, Desmopressin Adjuncts : Hemophilia A Treatment, Surgery Support, Genetic Deficiency Therapy, Prophylaxis Therapy : North America, Europe, Asia-Pacific, South America, Middle East & Africa : CSL Vifor, Octapharma, Grifols, BPL Plasma, LFB, Kedrion Biopharma, Bio Products Laboratory Limited, TAKEDA PHARMACEUTICALS AMERICA, INC., Sanofi, KAMADA, Green Cross Health, Octapharma Plasma, Inc., Baxalta, Catalyst Biosciences, Inhibrx Biosciences, Inc., Rigel Pharmaceuticals Inc., Aptevo Therapeutics Inc, Admac Oncology- Dedicated Oncology Facility, Thermo Fisher Scientific, Emergent BioSolutions, argenx, CSL, Fusion Pharmaceuticals, Medexus Pharmaceuticals, Sartorius, ProteinSimple, a Bio-Techne brand, Biotest AG, Viatris, Mallinckrodt Pharmaceuticals, HEMA Biologics, Catalent Pharma Solutions Brasil, Recipharm, Lonza, Zymeworks Inc., Alvotech, Arcturus Therapeutics, BioMarin Pharmaceutical Inc., Fresenius Kabi, West Pharmaceutical Services #humanfactorviii #pharmaceuticalresearch #hemophiliatherapy #recombinantdrugs #plasmaderivedproteins #biosimilarbiotech #blooddisorders #drugdevelopment #clinicalinnovation To view or add a comment, sign in More from this author Explore related topics Explore content categories

B-12, a crucial nutrient, plays an essential role in energy production, nerve function, and red blood cell formation
According to research, high MMP9 serum concentrations may increase the risk of atherosclerosis
Diabetes Care 2022;45:1252-9.PubMedPMC 856